All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Medicare Drug Price Negotiation Program Will Result in Financial Burdens for Community Oncology Practices

September 5th 2024

Debra Patt, MD, PhD, MBA, FASCO, highlights considerations with financial burdens that will be placed on community providers and oncology practices.

Novel Cell-Free DNA Assays Expand the Reach of MRD Detection in Lymphoma

September 5th 2024

Reid W. Merryman, MD, discusses notable advancements with minimal residual disease assays in lymphoma.

The Treatment of Rare Tenosynovial Giant Cell Tumors Is Poised to Shift

September 5th 2024

R. Lor Randall, MD, FACS, details how he treats patients with TGCTs and the potential of vimseltinib to join pexidartinib in the treatment landscape.

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL

September 4th 2024

Tisagenlecleucel is moving to earlier lines of therapy for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Novel Targets, Classes of Agents Could Refine Checkpoint Inhibition in NSCLC

September 4th 2024

Solange Peters, MD, PhD, discusses ways to refine checkpoint inhibition in the treatment of non–small cell lung cancer.

ASCO Palliative Care Expert Panel Provides Recommendations to Integrate Health Equity Into Guideline Development

September 4th 2024

The ASCO Palliative Care Expert Panel has offered recommendations to add health equity measures to their palliative care and other future guidelines.

Some Lung Cancer Disparities Lessen in South Florida

September 4th 2024

Racial/ethnic minorities are often diagnosed with lung cancer at later stages than White patients but that disadvantage is smaller in Hispanic populations.

IBI363 Receives FDA Fast Track Designation for Advanced/Metastatic Melanoma

September 4th 2024

The FDA has granted fast track designation to IBI363 for unresectable advanced or metastatic melanoma after progression on at least 1 line of therapy.

Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma

September 4th 2024

The phase 3 IOB-013/KN-D18 trial of IO102-IO103 plus pembrolizumab in advanced melanoma will continue without modifications.

A Decrease in Innovation Is a Large Concern With New IRA Policies in Oncology

September 4th 2024

Jeff Patton, MD, details considerations with the Medicare Drug Price Negotiation Program Draft Guidance and its effects in the community setting.

Baseline Radiologic Tumor Burden Is Prognostic for OS in Metastatic ccRCC

September 4th 2024

Rashad Nawfal, MD, discusses the association between radiologic tumor burden and OS in patients with metastatic ccRCC who had received frontline IO.

OncLive’s August Roundup of Key FDA Approvals in Oncology

September 4th 2024

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

A New Era of CAR-T Cell Therapy in Earlier Lines for Relapsed or Refractory Multiple Myeloma

September 4th 2024

FDA Green Lights Companion Diagnostics for Olaparib Plus Abiraterone Acetate in BRCA+ mCRPC

September 3rd 2024

The FDA approved companion diagnostics for olaparib plus abiraterone in metastatic castration-resistant prostate cancer.

Luspatercept Is Under Evaluation in Non-Transfusion Dependent Lower-Risk Myelodysplastic Syndrome

September 3rd 2024

The phase 3 ELEMENT-MDS trial aims to expand access to luspatercept for anemia in non-transfusion dependent lower-risk MDS.

Blinatumomab May Be an Effective Alternative to Consolidation Chemotherapy in Down Syndrome B-ALL

September 3rd 2024

Sujith Samarasinghe, BSc, MBBS, MRCPCH, FRCPath, PhD, discusses the use of blinatumomab in children with Down syndrome acute lymphoblastic leukemia.

Fox Chase Cancer Center Welcomes Dr Eric Goodlev

September 3rd 2024

Eric Goodlev, MD, has joined Fox Chase Cancer Center as an associate Professor in the Supportive Oncology and Palliative Care Program.

Azer-Cel Produces CRs in R/R DLBCL After Prior Autologous CAR T-Cell Therapy

September 3rd 2024

Azercabtagene zapreleucel produced complete responses in relapsed/refractory diffuse large B-cell lymphoma after prior autologous CAR T-cell therapy.

FDA Awards Fast Track Designation to CB-012 in Relapsed/Refractory AML

September 3rd 2024

The FDA has granted fast track designation to the allogeneic CAR T-cell therapy CB-012 for relapsed/refractory acute myeloid leukemia.

Vice President of COA Unpacks Effects of the Medicare Drug Price Negotiation Program in the Community

September 3rd 2024

Debra Patt, MD, PhD, MBA, FASCO, details how the Medicare Drug Price Negotiation Program Draft Guidance will affect community oncologists and practices.